title: Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso.
abstract: BACKGROUND
  Patient immune status is thought to affect the efficacy of anti-malarial chemotherapy. This is a subject of some importance, since evidence of immunity-related interactions may influence our use of chemotherapy in populations with drug resistance, as well as assessment of the value of suboptimal vaccines. The study aim was to investigate relationship between antibodies and anti-malarial drug treatment outcomes.
  
  
  METHODS
  Some 248 children aged 0.5 and 15 years were recruited prior to the high malaria transmission season. Venous blood (5 ml) was obtained from each child to measure antibody levels to selected malaria antigens, using ELISA. Blood smears were also performed to assess drug efficacy and malaria infection prevalence. Children were actively followed up to record clinical malaria cases.
  
  
  RESULTS
  IgG levels to MSP3 were always higher in the successfully treated group than in the group with treatment failure. The same observation was made for GLURP but the reverse observation was noticed for MSP1-19. Cytophilic and non-cytophilic antibodies were significantly associated with protection against all three antigens, except for IgG4 to MSP1-19 and GLURP.
  
  
  CONCLUSIONS
  Acquired anti-malarial antibodies may play an important role in the efficacy of anti-malarial drugs in younger children more susceptible to the disease.
authors.affiliation: Centre National de Recherche et de Formation sur le paludisme, o1 BP 2208 Ouagadougou 01, Burkina Faso. a.diarra.cnrfp@fasonet.bf
authors.forename: Amidou
authors.initials: A
authors.lastname: Diarra
authors.forename: Issa
authors.initials: I
authors.lastname: Nebie
authors.forename: Alfred
authors.initials: A
authors.lastname: Tiono
authors.forename: Issiaka
authors.initials: I
authors.lastname: Soulama
authors.forename: Alphonse
authors.initials: A
authors.lastname: Ouedraogo
authors.forename: Amadou
authors.initials: A
authors.lastname: Konate
authors.forename: Michael
authors.initials: M
authors.lastname: Theisen
authors.forename: Daniel
authors.initials: D
authors.lastname: Dodoo
authors.forename: Alfred
authors.initials: A
authors.lastname: Traore
authors.forename: Sodiomon B
authors.initials: SB
authors.lastname: Sirima
mesh_terms: D000293:Adolescent; D000913:Antibodies, Protozoan / Q000097:blood / Q000276:immunology*; D000962:Antimalarials / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D002050:Burkina Faso; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007223:Infant; D017780:Malaria Vaccines; D016778:Malaria, Falciparum / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000469:parasitology; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects / Q000276:immunology*; D015800:Protozoan Proteins / Q000097:blood*; D011739:Pyrimethamine / Q000008:administration & dosage*; D013413:Sulfadoxine / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000913:Antibodies, Protozoan; D000962:Antimalarials; D015415:Biomarkers; D004338:Drug Combinations; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D015800:Protozoan Proteins; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine